Joint partnership leverages Alpha Tau’s highly potent, localized alpha-radiation technology and Tolmar’s commercial leadership to transform the ...

Tolmar will invest $20 million in Alpha Tau at $11.99 per share, representing a 34% premium to the stock’s closing price on Tuesday. ・The deal also includes up to $161.5 million in potential ...

Alpha Tau CEO Uzi Sofer: "Tolmar is a well-established company in the field of urology in the US. We decided to grant exclusivity for one of our most promising but least advanced indications. In the ...

Shares of Alpha Tau Medical rose Wednesday after it said it will collaborate with Tolmar International to bring localized alpha radiation cancer therapy to prostate cancer patients in the United ...

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today ...

Abhinav Sidana, MD, a urologic oncologist at the University of Chicago Medicine (UChicago Medicine), has performed the first ...

Cleveland Clinic’s commercialization arm, Innovations, has spun off its fifth company this year in a joint project with an existing Cleveland startup. The new company is scooping up cancer diagnostic ...

Cigna Expands Commercial and Medicare AdvantageCoverage to Include Mdxhealth’s Select mdx for Prostate Cancer Test Expansion of coverage with Cigna now includes full menu of Company’s precision ...

Although the use of tissue-based gene expression testing for prostate cancer was found to be “highly variable in the United States at the regional level,” distinct regional trajectories of commercial ...